Blueprint Medicines Corporation BPMC reported fourth-quarter 2024 adjusted loss of 79 cents per share, wider than the Zacks ...

UBS initiated coverage of Celldex (CLDX) with a Buy rating and $44 price target The firm says KIT inhibition is “differentiated in the ...

Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

If your legs itch whenever you head out into the cold, it could be a sign of a health condition that can be life-threatening ...

The closely watched chronic spontaneous urticaria (CSU, or hives) space chalked more early stage KIT inhibitor data as Third Harmonic Bio Inc. rolled out results from the phase I single and multiple ...

Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

What if the food you eat and the way you handle stress could make a real difference for your chronic spontaneous urticaria?

Incyte says 2025 is expected to be a year of defining catalysts with four launches, four pivotal study readouts, at least ...

Hives, also known as urticaria, are raised, itchy welts on your skin that occur due to an allergen. The reaction is ...